Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.
about
Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring PlateletpheresisSpotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
P2860
Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@ast
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@en
type
label
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@ast
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@en
prefLabel
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@ast
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@en
P2093
P2860
P1476
Development of Romiplostim for ...... d Pharmacodynamic Perspective.
@en
P2093
Andrew T Chow
Bing-Bing Yang
Janet Franklin
Karen Arkam
Sameer Doshi
P2860
P2888
P304
P356
10.1007/S40262-016-0382-7
P577
2016-04-07T00:00:00Z
P6179
1019941236